Paroxysmal Nocturnal Hemoglobinuria

Healio’s look at how cancer clinic operators prepared for the second wave of COVID-19 cases was the top story in hematology/oncology last week.

The FDA granted breakthrough therapy designation to iptacopan for treatment of paroxysmal nocturnal hemoglobinuria.

The FDA granted priority review to pegcetacoplan for treatment of paroxysmal nocturnal hemoglobinuria, according to the agent’s manufacturer.

Eculizumab, which is only approved by the FDA for the treatment of three rare conditions, may be used frequently for off-label indications that lack strong scientific evidence, according to a study published in JAMA Internal Medicine.